- Home
- IMOS vs ABVX Comparison
IMOS vs ABVX Comparison
Compare IMOS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMOS
- ABVX
- Stock Information
- Founded
- IMOS 1997
- ABVX 2013
- Country
- IMOS Taiwan
- ABVX France
- Employees
- IMOS N/A
- ABVX N/A
- Industry
- IMOS Semiconductors
- ABVX
- Sector
- IMOS Technology
- ABVX
- Exchange
- IMOS Nasdaq
- ABVX Nasdaq
- Market Cap
- IMOS 551.9M
- ABVX 451.5M
- IPO Year
- IMOS N/A
- ABVX N/A
- Fundamental
- Price
- IMOS $19.15
- ABVX $8.15
- Analyst Decision
- IMOS
- ABVX Buy
- Analyst Count
- IMOS 0
- ABVX 4
- Target Price
- IMOS N/A
- ABVX $31.50
- AVG Volume (30 Days)
- IMOS 19.7K
- ABVX 246.0K
- Earning Date
- IMOS 05-13-2025
- ABVX 03-24-2025
- Dividend Yield
- IMOS 3.19%
- ABVX N/A
- EPS Growth
- IMOS N/A
- ABVX N/A
- EPS
- IMOS 0.05
- ABVX N/A
- Revenue
- IMOS $685,506,006.00
- ABVX $11,456,982.00
- Revenue This Year
- IMOS N/A
- ABVX $284.20
- Revenue Next Year
- IMOS $2.21
- ABVX N/A
- P/E Ratio
- IMOS $19.85
- ABVX N/A
- Revenue Growth
- IMOS 2.89
- ABVX 56.76
- 52 Week Low
- IMOS $12.78
- ABVX $4.77
- 52 Week High
- IMOS $27.80
- ABVX $14.71
- Technical
- Relative Strength Index (RSI)
- IMOS 63.41
- ABVX 74.16
- Support Level
- IMOS $18.13
- ABVX $5.59
- Resistance Level
- IMOS $19.36
- ABVX $8.61
- Average True Range (ATR)
- IMOS 0.66
- ABVX 0.44
- MACD
- IMOS -0.06
- ABVX 0.27
- Stochastic Oscillator
- IMOS 62.98
- ABVX 84.77
About IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.